Oncoinvent presents Radspherin® preclinical data at 30th Annual Congress of the European Association of Nuclear Medicine
Press Release 06.2017 · Work presented indicates that, with certain precautions, 224Ra based biomedical products can be used in a safe manner for the hospital staff and patients. · In vivo studies show that 224Ra-labeled CaCO3 microparticles could be safely administered in mice at therapeutically relevant doses and with a high degree of intraperitoneal retention. · The novel α-emitting microparticles have properties that make them a promising new modality for intracavitary cancer therapy.Oslo 23 October 2017 Oncoinvent, a preclinical stage company committed to developing new